Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes: Look AHEAD Ancillary Study.

In 30 seconds

This Look AHEAD ancillary study examined inflammatory biomarkers and cardiovascular outcomes in adults with type 2 diabetes and overweight or obesity. Adjusted Cox models assessed baseline hs-CRP and IL-6 in relation to atherosclerotic cardiovascular disease (ASCVD) and incident heart failure (HF); a randomized comparison assessed one-year IL-6 change with intensive lifestyle intervention (ILI) versus diabetes support and education. hs-CRP was not significantly associated with either outcome, whereas higher IL-6 was associated with incident HF (HR 1.43; 95% CI 1.16-1.75 per 1-SD higher log[IL-6]). ILI produced a greater IL-6 reduction.

Key findings

• After adjustment, hs-CRP was not significantly associated with ASCVD or incident HF.
• Higher IL-6 was associated with incident HF overall (HR: 1.43; 95% CI: 1.16-1.75 per 1-SD higher log[IL-6]).
• Among participants without prior CVD, the IL-6–HF association was stronger (HR: 1.92; 95% CI: 1.38-2.66 per 1-SD higher log[IL-6]; interaction P < 0.05).
• At one year, IL-6 reduction was greater with ILI than with diabetes support and education (-28.7% vs -11.8%; P = 0.01).

Why it matters

The findings distinguish inflammatory markers by outcome: hs-CRP did not identify adjusted ASCVD or HF risk, while IL-6 was associated with incident HF, particularly in participants without prior CVD. The randomized intervention comparison also shows that intensive lifestyle intervention can reduce IL-6 over one year, although the abstract does not establish that this biomarker change reduces HF events.

What to keep in mind

The biomarker-outcome analyses were observational associations, so they do not establish that IL-6 causes HF. The abstract reports one-year biomarker change but does not report whether intervention-related IL-6 reduction altered clinical outcomes.